All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2017; the latest 2025-05-23.
From the record
Q32 Bio Inc.'s filings since 2017 show 3 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2025-05-23); an auditor change (8-K item 4.01, the latest 2024-03-27) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+46.6% a year over 4 filed years; profitable in 1 of 8.
From the record
Q32 Bio Inc.'s 4 filed years say what it did: revenue went from $4 million in fiscal 2018 to $54 million in fiscal 2025, up 46.6% a year; it rose in 0 of 1 years; the deepest fall was 281% from fiscal 2018 to fiscal 2023; net income was positive in 1 of 8 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 9.9/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Q32 Bio Inc.'s shareholder treatment is put at 9.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 1% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE 71%: 71¢ of profit per shareholder dollar. Leverage 32%: owes 32¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Q32 Bio Inc. earned about 71 cents of profit for every dollar of shareholders' money. Leverage: it owed about 32 cents per dollar of assets, and net share issuance: its share count grew 27.5% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 24% of 315 in its family; net margin 55.5%.
From the record
Q32 Bio Inc.'s standing among 315 graded names in its industry family: revenue of $54 million in fiscal 2025 ranks in the top 43% by size; a net margin of 55.5% ranks in the top 5%; revenue growth of 46.6% a year over the last 3 filed years ranks in the top 24% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 5.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Q32 Bio Inc.'s leadership is put at 5.1 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 49% of 415 in its family; the record of its people begins on 2024-03-27 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.6 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
top 43% of 273 in its family for room to expand.
From the record
Q32 Bio Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $48 million against no long-term debt tagged leaves 78.2% of its assets as net cash, top 19% of its family; cash from operations less capital spending is -62.4% of revenue (top 47%); research spending of 35.6% of revenue (bottom 37%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 33% of 306 in its family for growth drivers.
From the record
Q32 Bio Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 46.6% a year over the last three filed years against 46.6% over all 4, speeding up (top 40% of its family); research spending grew -42% a year (bottom 6%) (its annual reports). Q32 Bio Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 9.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Q32 Bio Inc.'s expectations vs reality is put at 9.1 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the top 9% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made